Ratings Noritsu Koki Co., Ltd. OTC Markets

Equities

NKOKF

JP3759500006

Market Closed - OTC Markets Other stock markets 15:07:54 14/11/2023 GMT			5-day change	1st Jan Change
20 ^USD	-.--%		-.--%	-.--%

05-31	MediPal Holdings Corporation completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd..	CI
04-30	MediPal Holdings Corporation agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. for ¥3.8 billion.	CI

Strengths

The company's share price in relation to its net book value makes it look relatively cheap.
The company has a low valuation given the cash flows generated by its activity.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.

Ratings chart - Surperformance

Sector: Recreational Products

	1st Jan change	Capi.	ESG Refinitiv
NORITSU KOKI CO., LTD.	-.--%	975M	-
THOR INDUSTRIES, INC.	-22.21%	4.89B	B-
BRUNSWICK CORPORATION	-28.21%	4.69B	B+
BRP INC.	-9.23%	4.68B	A-
POLARIS INC.	-21.66%	4.2B	B-
YETI HOLDINGS, INC.	-28.18%	3.17B	C-
GIANT MANUFACTURING CO., LTD.	+15.22%	2.56B	B-
TRIGANO	-23.53%	2.37B	C
WINNEBAGO INDUSTRIES, INC.	-28.87%	1.5B	B-
FUSHENG PRECISION CO., LTD.	+31.96%	1.11B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes